• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: W. L. GORE & ASSOCIATES, INC. GORE® INTERING® VASCULAR GRAFT; PROSTHESIS, VASCULAR GRAFT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

W. L. GORE & ASSOCIATES, INC. GORE® INTERING® VASCULAR GRAFT; PROSTHESIS, VASCULAR GRAFT Back to Search Results
Model Number IRS47045L
Medical Device Problem Code Patient Device Interaction Problem (4001)
Health Effect - Clinical Code Hematoma (1884)
Date of Event 03/16/2021
Type of Reportable Event Serious Injury
Event or Problem Description
The following information was reported to gore: on december 2, 2021, a gore® intering® vascular graft was intended for hemodialysis treatment.On (b)(6) 2022, the patient presented with seroma.A gore® intering® vascular graft was sewn in as a interposition graft.On april 20, 2022, the patient presented with seroma.A gore® viabahn® endoprosthesis (vsx device) was endovascularly placed to reline the second gore® intering® vascular graft, for treatment of ultrafiltration.Ultrafiltration was identified during the procedure after the vsx device was successfully implanted.On (b)(6) 2022, the gore® intering® vascular graft, and vsx device were explanted.2203-a:-other code (post-operative fluid leakage through vsx device wall after establishment of blood flow).
 
Additional Manufacturer Narrative
Section h6 updated to reflect completion of investigation.Manufacturing records were reviewed, and the device met all pre-release specifications.Explant evaluation: the specimens were not properly stored in a fixative solution for proper preservation of the tissue on and within the fragments.Therefore, a histopathological examination of the tissue could not be performed, due to the lack of proper fixation prior to arrival at w.L.Gore & associates.The specimens were subjected to an enzymatic digestion process to remove biologic debris.Following digestion all specimens were examined for material disruptions with the aid of a stereomicroscope.After initial analysis, the specimens were separated and re-examined.Prior to separation, the luminal surface of the viabahn fragments presented with an undulating pattern of the material.The material disruptions identified (i.E., forceps marks, transections, anastomotic holes) were consistent with those caused by interaction with surgical instrumentation (i.E., forceps/clamps, scalpel/scissors, anastomotic suturing), likely used during a surgical procedure.There was no evidence of a material disruption that would contribute to ultrafiltration.The cause of ultrafiltration could not be determined with the information and specimens provided.Cause of the reported event cannot be established based on evaluation of the returned specimen and the information reported to gore.Further information regarding this event was requested by gore, but no further information has been reported, therefore this investigation is considered complete.
 
Additional Manufacturer Narrative
Section h6 updated to reflect completion of investigation.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
GORE® INTERING® VASCULAR GRAFT
Common Device Name
PROSTHESIS, VASCULAR GRAFT
Manufacturer (Section D)
W. L. GORE & ASSOCIATES, INC.
1505 n. fourth street
flagstaff AZ 86004
Manufacturer (Section G)
MEDICAL WEST B/P
1505 n. fourth street
flagstaff AZ 86004
Manufacturer Contact
nick lafave
1505 n. fourth street
flagstaff, AZ 86004
9285263030
MDR Report Key14604839
Report Number2017233-2022-02988
Device Sequence Number12022145
Product Code DSY
UDI-Device Identifier00733132607204
UDI-Public00733132607204
Combination Product (Y/N)N
Initial Reporter StateLA
Initial Reporter CountryUS
PMA/510(K) Number
K991602
Number of Events Summarized1
Summary Report (Y/N)N
Device Implanted Year2022
Device Explanted Year2022
Reporter Type Manufacturer
Report Source Company Representative
Initial Reporter Occupation Physician
Type of Report Initial,Followup,Followup
Report Date (Section B) 10/24/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Operator of Device Health Professional
Device Expiration Date05/31/2026
Device Model NumberIRS47045L
Device Catalogue NumberIRS47045L
Was Device Available for Evaluation? Yes
Is the Reporter a Health Professional? Yes
Type of Report(Section G)Initial
Initial Date Received by Manufacturer 05/12/2022
Supplement Date Received by Manufacturer08/19/2022
10/24/2022
Initial Report FDA Received Date06/06/2022
Supplement Report FDA Received Date08/26/2022
10/24/2022
Was Device Evaluated by Manufacturer? (Y/N) Device Not Returned to Manufacturer
Date Device Manufactured06/28/2021
Is the Device Labeled for Single Use? (Y/N) Yes
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
Patient Sequence Number1
Outcome Attributed to Adverse Event Required Intervention; Hospitalization; Other;
Patient SexUnknown
-
-